Susquehanna International Group, LLP Biogen Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$189.07 - $236.8 $20.6 Million - $25.8 Million	108,800 Added 33.79%	430,800 $83.5 Million
Q2 2024 Aug 15, 2024	SELL	$190.52 - $236.72 $38.8 Million - $48.2 Million	-203,700 Reduced 38.75%	322,000 $74.6 Million
Q1 2024 May 07, 2024	BUY	$212.02 - $267.71 $2.52 Million - $3.19 Million	11,900 Added 2.32%	525,700 $113 Million
Q4 2023 Feb 14, 2024	BUY	$222.59 - $267.94 $31.6 Million - $38 Million	141,800 Added 38.12%	513,800 $133 Million
Q3 2023 Nov 14, 2023	SELL	$253.3 - $285.89 $30.5 Million - $34.4 Million	-120,300 Reduced 24.44%	372,000 $95.6 Million
Q2 2023 Aug 11, 2023	SELL	$275.25 - $318.06 $74.9 Million - $86.6 Million	-272,200 Reduced 35.6%	492,300 $140 Million
Q1 2023 May 16, 2023	SELL	$256.56 - $292.34 $159 Million - $181 Million	-619,200 Reduced 44.75%	764,500 $213 Million
Q4 2022 Feb 14, 2023	SELL	$252.44 - $306.72 $47.6 Million - $57.9 Million	-188,700 Reduced 12.0%	1,383,700 $383 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $135 Million - $186 Million	694,000 Added 79.01%	1,572,400 $420 Million

1,036

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $22.7B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.